Medical update: final. Let me just conclude with three thoughts.
for antibiotics. In my case, azithromycin.
Two, given what I've been going through, how is it possible that drug companies will
be the huge winners of the next 10 years?
Finally, many, many of you were thoughtful enough to send me "get well soon" emails. They were all extremely appreciated. Thank you.
And now the end of this series, with a look at some of my current favorites. I'm often asked what are -- or would be -- my buy-and-hold stocks? With that in mind, I picked five of my favorites, and looked at each not on a daily chart, but a monthly one. In addition, I also believe in each of these companies from a fundamental perspective. No surprises, I'm afraid, but still, a solid list of winners. Let's see if you agree.
Next week, look for my Monday column on Tuesday. By then, I should almost be at full speed!
Gary B. Smith is a freelance writer who trades for his own account from his Maryland home using technical analysis. At time of publication, he held no positions in any securities mentioned in this column, although holdings can change at any time. Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. Smith writes five technical analysis columns for TheStreet.com each week, including Technician's Take, Charted Territory and TSC Technical Forum. While he cannot provide investment advice or recommendations, he welcomes your feedback at